XML 15 R2.htm IDEA: XBRL DOCUMENT v2.4.0.6
CONSOLIDATED BALANCE SHEETS (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2012
Dec. 31, 2011
CURRENT ASSETS    
Cash and cash equivalents $ 8,787 $ 5,846
Short-term bank deposits 13,107 16,525
Restricted cash 91 92
Other accounts receivable and prepaid expenses (note 5b3) 650 546
Total current assets 22,635 23,009
LONG-TERM INVESTMENTS:    
Investment in Evogene 4,662 4,093
Long-term lease deposits 68 17
Severance pay fund 1,527 1,465
Total long-term investments 6,257 5,575
LONG-TERM PREPAID EXPENSES (note 5b3) 400   
PROPERTY AND EQUIPMENT, NET 696 497
Total assets 29,988 29,081
CURRENT LIABILITIES:    
Trade payables 335 248
Other accounts payable and accrued expenses 1,207 1,459
Total current liabilities 1,542 1,707
LONG-TERM LIABILITIES:    
Research and development funding arrangements 4,793 6,150
Accrued severance pay 1,766 1,643
Total long-term liabilities 6,559 7,793
SHAREHOLDERS' EQUITY (Note 6):    
Share capital: Ordinary shares of NIS 0.01 par value: 100,000,000 shares authorized at June 30, 2012 and December 31, 2011; 35,990,311 and 34,707,622 shares issued and outstanding at June 30, 2012 and December 31, 2011, respectively 97 94
Additional paid-in capital 202,193 195,714
Accumulated other comprehensive income 4,833 4,264
Accumulated deficit (185,236) (180,491)
Total shareholder' equity 21,887 19,581
Total liabilities and shareholders' equity $ 29,988 $ 29,081